AIM: To derive a Malaysia guideline and consensus as part of the Malaysia Retina Group’s efforts for diagnosis, treatment, and best practices of diabetic macular edema (DME). The experts’ panel suggests that the treatment algorithm to be divided into groups according to involvement the central macula. The purpose of DME therapy is to improve edema and achieve the best visual results with the least amount of treatment load. METHODS: On two different occasions, a panel of 14 retinal specialists from Malaysia, together with an external expert, responded to a questionnaire on management of DME. A consensus was sought by voting after compiling, analyzing and discussion on first-phase replies on the round table discussion. A recommendation was deemed to have attained consensus when 12 out of the 14 panellists (85%) agreed with it. RESULTS: The terms target response, adequate response, nonresponse, and inadequate response were developed when the DME patients’ treatment responses were first characterized. The panelists reached agreement on a number of DME treatment-related issues, including the need to classify patients prior to treatment, first-line treatment options, the right time to switch between treatment modalities, and side effects associated with steroids. From this agreement, recommendations were derived and a treatment algorithm was created. CONCLUSION: A detail and comprehensive treatment algorithm by Malaysia Retina Group for the Malaysian population provides guidance for treatment allocation of patients with DME.

1. Chauhan MZ, Rather PA, Samarah SM, Elhusseiny AM, Sallam AB. Current and novel therapeutic approaches for treatment of diabetic macular edema. Cells 2022; 11(12): 1950.
2. Gurreri A, Pazzaglia A. Diabetic macular edema: state of art and intraocular pharmacological approaches. Adv Exp Med Biol 2021; 1307: 375-389.
3. Xiong K, Gong X, Li WT, Yuting L, Meng J, Wang LH, Wang W, Wenyong H. Comparison of macular thickness measurements using swept-source and spectral-domain optical coherence tomography in healthy and diabetic subjects. Curr Eye Res 2021; 46(10): 1567-1573.
4. Wykoff CC, Khurana RN, Nguyen QD, Kelly SP, Lum F, Hall R, Abbass IM, Abolian AM, Stoilov I, To TM, Garmo V. Risk of blindness among patients with diabetes and newly diagnosed diabetic retinopathy. Diabetes Care 2021; 44(3): 748-756.
5. Thomas RL, Halim S, Gurudas S, Sivaprasad S, Owens DR. IDF Diabetes Atlas: a review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. Diabetes Res Clin Pract 2019; 157: 107840.
6. Chew FLM, Salowi MA, Mustari Z, Husni MA, Hussein E, Adnan TH, Ngah NF, Limburg H, Goh PP. Estimates of visual impairment and its causes from the National Eye Survey in Malaysia (NESII). PLoS One 2018; 13(6): e0198799.
7. Gale MJ, Scruggs BA, Flaxel CJ. Diabetic eye disease: a review of screening and management recommendations. Clin Exp Ophthalmol 2021; 49(2): 128-145.
8. Murthy GVS. Situational analysis of diabetic retinopathy screening in India: how has it changed in the last three years? Indian J Ophthalmol 2021; 69(11): 2944-2950.
9. Bopp S, Kellner U. Pars plana vitrectomy. Klin Monbl Augenheilkd 2019; 236(5): 705-722.
10. Kwan CC, Fawzi AA. Imaging and biomarkers in diabetic macular edema and diabetic retinopathy. Curr Diab Rep 2019; 19(10): 95.
11. Hagenau F, Vogt D, Ziada J, Guenther SR, Haritoglou C, Wolf A, Priglinger SG, Schumann RG. Vitrectomy for diabetic macular edema: optical coherence tomography criteria and pathology of the vitreomacular interface. Am J Ophthalmol 2019; 200: 34-46.
12. Koc F, Güven YZ, Egrilmez D, Aydın E. Optical coherence tomography biomarkers in bilateral diabetic macular edema patients with asymmetric anti-VEGF response. Semin Ophthalmol 2021; 36(5-6): 444-451.
13. Chou HD, Wu CH, Chiang WY, Chen NN, Hwang YS, Chen KJ, Lai CH, Wu PC, Chen YH, Yeung L, Shao SC, Lai CC, Wu WC. Optical coherence tomography and imaging biomarkers as outcome predictors in diabetic macular edema treated with dexamethasone implant. Sci Rep 2022; 12(1): 3872.
14. Lai CT, Hsieh YT, Lin CJ, Wang JK, Lin CY, Hsia NY, Bair H, Chen HS, Chiu CY, Weng SW. Age, initial central retinal thickness, and OCT biomarkers have an influence on the outcome of diabetic macular edema treated with ranibizumab- tri-center 12-month treat-and-extend study. Front Med (Lausanne) 2021; 8: 668107.
15. Das R, Spence G, Hogg RE, Stevenson M, Chakravarthy U. Disorganization of inner retina and outer retinal morphology in diabetic macular edema. JAMA Ophthalmol 2018; 136(2): 202-208.
16. Huang YT, Chang YC, Meng PP, et al. Optical coherence tomography biomarkers in predicting treatment outcomes of diabetic macular edema after dexamethasone implants. Front Med (Lausanne) 2022; 9: 852022.
17. Fragiotta S, Abdolrahimzadeh S, Dolz-Marco R, Sakurada Y, Gal-Or O, Scuderi G. Significance of hyperreflective foci as an optical coherence tomography biomarker in retinal diseases: characterization and clinical implications. J Ophthalmol 2021; 2021: 6096017.
18. Schreur V, Altay L, van Asten F, et al. Hyperreflective foci on optical coherence tomography associate with treatment outcome for anti-VEGF in patients with diabetic macular edema. PLoS One 2018; 13(10): e0206482.
19. Călugăru D, Călugăru M. Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment. Graefes Arch Clin Exp Ophthalmol 2018; 256(5): 1035-1037.
20. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118(4): 615-625.
21. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS, and RIDE Research Group RISE. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: rise and RIDE. Ophthalmology 2012; 119(4): 789-801.
22. Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121(10): 1904-1914.
23. Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer D, Holz FG, Heier JS, Midena E, Kaiser P, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Brown DM. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121(11): 2247-2254.
24. Network DRCR, Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117(6): 1064-1077.e35.
25. Network DRCR, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372(13): 1193-1203.
26. Curry BA, Sanfilippo PG, Chan S, Hewitt AW, Verma N. Clinical outcomes of a treat and extend regimen with intravitreal aflibercept injections in patients with diabetic macular edema: experience in clinical practice. Ophthalmol Ther 2020; 9(1): 87-101.
27. Aderman CM, Garg SJ. Intravitreal anti-VEGF injection treatment algorithms for DME. Retina Today 2017; 4: 53- 55.
28. Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol 2016; 134(1): 21-29.
29. Zarbin MA, Dunger-Baldauf C, Haskova Z, Koovejee P, Mousseau MC, Margaron P, Snow H, Beaumont PE, Staurenghi G, Francom S. Vascular safety of ranibizumab in patients with diabetic macular edema: a pooled analysis of patient-level data from randomized clinical trials. JAMA Ophthalmol 2017; 135(5): 424-431.
30. Jain P, Sheth J, Anantharaman G, Gopalakrishnan M. Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. Indian J Ophthalmol 2017; 65(7): 596-602.
31. Bucolo C, Gozzo L, Longo L, Mansueto S, Vitale DC, Drago F. Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies. J Pharmacol Sci 2018; 138(4): 219-232.
32. Pai A, El Shafei MM, Mohammed OAZ, Al Hashimi M. Current concepts in intravitreal drug therapy for diabetic retinopathy. Saudi J Ophthalmol 2010; 24(4): 143-149.
33. Yau GL, Silva PS, Arrigg PG, Sun JK. Postoperative complications of pars Plana vitrectomy for diabetic retinal disease. Semin Ophthalmol 2018; 33(1): 126-133.
34. Mathew C, Yunirakasiwi A, Sanjay S. Updates in the management of diabetic macular edema. J Diabetes Res 2015; 2015: 794036.
35. Rajalakshmi R, Prathiba V, Mohan V. Does tight control of systemic factors help in the management of diabetic retinopathy? Indian J Ophthalmol 2016; 64(1): 62-68.
36. Chhablani J, Wong K, Tan GS, Sudhalkar A, Laude A, Cheung CMG, Zhao P, Uy H, Lim J, Valero S, Ngah NF, Koh A. Diabetic macular edema management in Asian population: expert panel consensus guidelines. Asia Pac J Ophthalmol (Phila) 2020; 9(5): 426-434.
37. Peracha ZH, Rosenfeld PJ. Managing DME during pregnancy-Intravitreal steroids may be considered in cases refractory to blood glucose control and laser. Retina Specialist 2015.
38. Rosenthal JM, Johnson MW. Management of retinal diseases in pregnant patients. J Ophthalmic Vis Res 2018; 13(1): 62-65.
39. Yoo R, Kim HC, Chung H. Dexamethasone intravitreal implant for diabetic macular edema in a pregnant patient. Int J Ophthalmol 2016; 9(10): 1524-1527.
40. Medeiros MD, Alkabes M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B. Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema. J Ocul Pharmacol Ther 2014; 30(9): 709-716.
41. Lakhani BK, Giannouladis K, Leighton P, King AJ. Seeking a practical definition of stable glaucoma: a Delphi consensus survey of UK glaucoma consultants. Eye (Lond) 2020; 34(2): 335-343.
42. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011; 31(4): 654-661.
43. Kiss S, Dugel PU, Khanani AM, Broder MS, Chang E, Sun GH, Turpcu A. Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis. Clin Ophthalmol 2018; 12: 1625-1635.
44. Goel N. Acute bacterial endophthalmitis following intravitreal dexamethasone implant: a case report and review of literature. Saudi J Ophthalmol 2017; 31(1): 51-54.
45. Kaštelan S, Orešković I, Bišćan F, Kaštelan H, Gverović Antunica A. Inflammatory and angiogenic biomarkers in diabetic retinopathy. Biochem Med (Zagreb) 2020; 30(3): 030502.
46. Vujosevic S, Toma C, Villani E, Muraca A, Torti E, Florimbi G, Leporati F, Brambilla M, Nucci P, De Cilla’ S. Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids. Acta Diabetol 2020; 57(3): 287-296.
47. García-Quintanilla L, Luaces-Rodríguez A, Gil-Martínez M, et al. Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration. Pharmaceutics 2019; 11(8): 365.
48. Edington M, Connolly J, Chong NV. Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes. Expert Opin Drug Metab Toxicol 2017; 13(12): 1217-1224.
49. Orii Y, Gozawa M, Takamura Y, Takeuchi Y, Morioka M, Yamada Y, Matsumura T, Sugimoto M, Inatani M. Comparison of the intraocular pressure following an intravitreal triamcinolone acetonide injection for diabetic macula oedema in vitrectomised and non-vitrectomised eyes. BMJ Open Ophthalmol 2021; 6(1): e000620.
50. Kishore K, Bhat PV, Venkatesh P, Canizela CC. Dexamethasone intravitreal implant for the treatment of macular edema and uveitis: a comprehensive narrative review. Clin Ophthalmol 2022; 16: 1019-1045.
51. Lobo C, Santos T, Marques IP, Madeira MH, Santos AR, Figueira J, Cunha-Vaz J. Characterisation of progression of macular oedema in the initial stages of diabetic retinopathy: a 3-year longitudinal study. Eye (Lond) 2023; 37(2): 313-319.
52. Zaytseva OV, Neroeva NV, Okhotsimskaya TD, Bobykin EV. Anti-VEGF therapy for neovascular age-related macular degeneration: causes of incomplete response. Vestn Oftalmol 2021; 137(5): 152-159.
53. Minaker SA, Mason RH, Lahaie Luna G, Farahvash A, Garg A, Bhambra N, Bapat P, Muni RH. Changes in aqueous and vitreous inflammatory cytokine levels in diabetic macular oedema: a systematic review and meta-analysis. Acta Ophthalmol 2022; 100(1): e53-e70.
54. Sudhalkar A, Kodjikian L, Chhablani J, Bhojwani D, Vasavada A. Intraocular dexamethasone implant position in situ and ocular hypertension. Retina 2018; 38(12): 2343-2349.
55. Granstam E, Rosenblad A, Modher Raghib A, Granström T, Eriksson JW, Lindholm Olinder A, Leksell J. Long-term follow-up of antivascular endothelial growth factor treatment for diabetic macular oedema: a four-year real-world study. Acta Ophthalmol 2020; 98(4): 360-367.
56. Obadă O, Pantalon AD, Rusu-Zota G, Hăisan A, Lupuşoru SI, Chiseliţă D. Choroidal assessment in patients with type 2 diabetes mellitus and non-proliferative diabetic retinopathy by swept-source ocular coherence tomography and image binarization. Medicina (Kaunas) 2022; 58(7): 918.
57. O’Fee JR, Juliano J, Moshfeghi AA. Factors associated with diabetic macular edema in patients with proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2022; 260(7): 2191-2200.